COHANCE Rolling Returns

Over 5 years, Cohance Lifesciences Ltd. has been through 18 separate 5 years holding periods — one starting every month. The median returned 5.8% a year, the worst -9.1% and the best 63.7%. A rolling return measures every possible start date instead of one, which is why it answers a question a single headline CAGR cannot: how much the outcome depended on when you happened to buy.

Yes. 44.4% of the 18 5 years periods on record ended below where they started, and the worst of them lost 9.1% a year — the stretch beginning March 2021. The median period returned 5.8% a year.

-9.1% a year, for the five years beginning March 2021. For contrast the best 5 years returned 63.7% a year, starting March 2020, and the median across all 18 periods was 5.8%. The gap between those two numbers is the part of the outcome that came down to timing rather than to the company.

On this record, yes. 1 year outcomes ranged from -74.5% to 395.2% a year — a spread of 469.7%. 5 years outcomes ranged from -9.1% to 63.7%, a spread of 72.8%. Longer holding periods narrowed the range of results, which is the usual pattern and the reason this page publishes every window rather than one. Narrowing the range is not the same as removing the risk.

In 44.4% of the 18 5 years periods both series cover. Each window is compared against the index over the identical months, not against an assumed index return, so the comparison is a like-for-like record rather than a model.

Windows step forward one month at a time on month-end closing prices adjusted for dividends and stock splits, so dividends are treated as reinvested. A window length is only published once there are at least twelve complete windows behind it — fewer than that describes an anecdote, not a distribution. Overlapping windows share months by construction, which is what makes this a description of the actual history of Cohance Lifesciences Ltd. rather than a sample of independent trials. Companies that delisted are not on this site at all, a survivorship bias worth holding in mind.

That is not a question this page answers, and we do not make recommendations. What it can show you is the full range of what every holding period in the listed history of Cohance Lifesciences Ltd. actually produced — including the worst ones, which most performance figures leave out. Those are records of what happened, not forecasts. A stock that never had a losing decade may still have one, and holding a single company is a materially different risk from holding an index.